AXIOS September 10, 2024
Tina Reed

A fight is brewing between drug giants and pharmacy compounders that have seized on the consumer demand for blockbuster obesity drugs.

Why it matters: The clash is testing the boundaries of Food and Drug Administration policy that allows pharmacies to make versions of drugs — including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy — that are otherwise protected by patents when there are shortages.

The big picture: Both legitimate and illegitimate companies have raced to fill the gaps in GLP-1 obesity drug availability by making copies of their active ingredients — semaglutide and tirzepatide — at a much lower price than the branded drugs.

  • Compounders say they’re improving access for people who have been prescribed GLP-1s for diabetes...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
NVIDIA AI Summit 2024: More Storage and Computing Capabilities Advance Genomic Research
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
City Therapeutics' $135m debut, and other bio financing news
Leverage AI to Lower Cost, Barriers to Cell Therapies
Robust Evidence Synthesis To Support Transparent Medicare Drug Price Negotiation

Share This Article